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KEY POINTS (3-5) 
• Allergic contact dermatitis belongs to the most frequent work-related conditions 
• Clinical features chronic allergic and irritant contact dermatitis may overlap 
• Identification of the offending allergen in ACD is often circumstantial 
• New techniques are required to overcome these old challenges 
 
SYNOPSIS (1-paragraph) 
Allergic contact dermatitis (ACD) is a frequent skin disease due to a T cell mediated immune reaction 
to usually innocuous allergens that get in contact with skin. In a chronic stage and especially when a 
work-related compound is the allergen, ACD can have grave medical and socio-economic 
consequences. ACD and irritant contact dermatitis (ICD) often occur together. A detailed history and 
clinical examination are crucial and guide patch testing that is the gold standard to diagnose ACD. T 
cell clones persisting in the skin may explain the tendency of ACD to relapse even after years of 
allergen avoidance. Traditional treatments for ACD are topical steroids, calcineurin inhibitors, 
phototherapy, retinoids including the recent alitretinoin, and immunosuppressants. Targeted therapies 
are as yet lacking.  
 
 
  
Introduction 
Allergic contact dermatitis (ACD) seems a straightforward and simple disease. The problem is easily 
defined – it’s a cutaneous immune reaction against one or more non-toxic allergens that come in 
contact with the skin. So all the patient should need to do is getting rid of the allergen. But in reality, 
detection, allergen avoidance and therapy are often very difficult. Therefore, ACD can plague patients 
for years and is a grave socioeconomic problem today.  
ACD and irritant contact dermatitis can lead to clinically mostly similar phenotypes, even though the 
latter is much more frequent and not due to an immune reaction to well-defined allergens. Together 
they make up more than 90% of occupational skin disorders. Affected patients suffer from great 
impairment in their quality of life and experience long periods of sick leave, which has an important 
socioeconomic impact. 
The one-year prevalence for allergic contact eczema is about 15% [1, 2]. Therefore it concerns groups 
of all ages with high prevalence and incidence, even though elderly people are often affected due to 
marred epidermal barriers or due to alterations of immune reactivity [3]. The two main groups of 
contact eczema coexist in many cases and the differentiation between them often proves to be 
difficult. Both diseases can have similar clinical and histological aspects. 
 
Epidemiology 
4-7% of all dermatology consultations are due to contact dermatitis. In Sweden, about 10-12% of 
adults suffered of hand eczema during the span of one year. The tendency for ACD is dropping 
slightly, however, and inversely mirrored by the rise of atopic dermatitis. The point prevalence of 
contact sensitivity is 15.2% in teenagers. In adults, this is much higher and can reach 18.6%. This may 
be mostly due to the cumulative opportunities of sensitization rather than an effect of the age, as the 
latter does not have a direct influence on capability for sensitization. The prevalence of pure ACD is 
difficult to measure as allergic and irritant contact dermatitis usually co-exist. The incidence of 
occupational dermatitis per 1000 workers and year is about 0.5 - 1.9 in most European countries.  
 
Pathomechanism 
The allergic contact dermatitis develops only after an initial sensitization [4] phase with usually 
innocuous substances. These are small molecules that cannot be recognized on their own by the 
adaptive immune system. When they are bound to cutaneous proteins, however, they can associate 
with major histocompatibility antigens class II (MHC II). Some chemicals can also directly bind to MHC 
II that are present on Langerhans cells and other epidermal antigen-presenting cells, mostly of 
dendritic origin. After application, it takes about 6 hours until the allergen is presented on these cells. 
Additional signals such as inflammatory cytokines (TNF-α, IL1-β, others) can support sensitization and 
could arise from irritation of the skin, perhaps explaining the close connection of allergy and irritation in 
this disease. Also, MHC molecules are upregulated. The activation (priming) of specific T cells takes 
place in the lymph nodes. The antigen presenting cells migrate there and depending on the nature of 
the antigen present it on MHC class II (i.e. a polar hapten) or MHC class I (i.e. the small lipid soluble 
molecule urushiol).  T cells will then proliferate in the lymph nodes, primed T cell clones will start to 
disseminate throughout the skin of the body, and cutaneous lymphocyte antigen (CLA) positive T cells 
stay thereafter in the skin for long periods of time [5]. Activated T-cells produce cytokines such as IFN-
γ, IL-2 and IL-17. They are attracted by keratinocyte-derived CCL27 that binds to their CCR10 to the 
locus of inflammation. T cells have an apoptotic effect on keratinocytes due to their FasL and perforin 
expression. These effects combined ultimately lead to the clinical phenotype of ACD. Taken together, 
the delayed hypersensitivity reaction is due to the previously activated T-cells, which only at second 
contact causes rapid inflammation [6, 7]. As an exception, a single, prolonged contact with an allergen 
may lead to ACD, but this should require several days to develop. The sensitization phase is specific 
for ACD and is not a feature of irritant contact dermatitis (ICD), even though in both conditions, largely 
similar clinical features develop. In ICD, the inflammation is rather due to the irritant itself, which – 
somewhat in contrast to ACD – is dose dependent. 
 
Clinical Features  
ACD presents with erythema, edema, vesicles, oozing and notably intense pruritus. In the mildest 
form, only erythema is visible at the site of contact – sometimes, the type of substance can be already 
suspected i.e. when liquid tracks are visible. Stronger reactions include spongiotic vesicles that itch 
and burst quickly, weeping intensively and crusting thereafter (Figure 1a,b). In ACD due to a single 
exposure, all lesions are at the same stage in this process [8]. When it becomes chronic, the term 
eczema is used and features such as hyperkeratosis, desquamation, lichenification and fissuring 
become more prominent [9] (Figure 1c). The lesion is then less sharply circumscribed, infiltration and 
thickness of skin increases, lichenification marks develop and regional differences in the stage of the 
inflammation can be seen. The localization plays an important role for the morphology of ACD – even 
though it can occur on every part of the body. Also, the body site gives important clues to the etiology 
of ACD and is the starting point for detailed history taking, which is crucial to guide patch testing for 
identification of the responsible allergen. When it comes to delicate areas with a thin stratum corneum 
such as the eyelids, penis and scrotum, erythema and edema usually outweight papules and vesicles. 
The same clinical features appear in allergic contact stomatitis and vulvitis [9]. An allergic contact 
reaction is typically not sharply limited. It is predominant in the area of contact, but can widely spread 
to other areas. In ectopic ACD, the allergen reaches the patients’ skin by exceptional routes [7]: 
− Autotransfer: e.g. with nail lacquer located on the eyelids or on the neck (transfer by fingers) 
− Heterotransfer: transfer of the allergen to another person, mainly the partner, also known as 
„connubial ACD“ 
− Airborne ACD: transport of the contact allergen by air (dust particles, vapours or gasses, e.g. from 
wall paint or pollen), typically clinical lesions on uncovered areas 
− Photo-allergic ACD: from UV light, clinical lesions on light-exposed zones, typically spares areas 
covered with clothes or shaded by hair such as ears or scalp 
 
Sometimes, generalized contact dermatitis can occur. The pathomechanism remains unclear. 
Exposure to high doses of allergens, dissemination via blood vessels or a generalized activation of 
immunologic effector cells have all been put forward as potential explanations [10]. Atypical forms of 
ACD are dyshidrotic and pompholyx-type contact dermatitis, erythema multiforme-like reactions, 
pigmented purpura, pustular reactions, granulomas and scleroderma-like lesions [8].  
 
In contrast, acute irritative-toxic dermatitis, can present, apart from edema, erythema, vesicles, bullae 
and oozing, with pustules, ulceration and necrosis. It can also be characterized by dryness and 
roughness, while the chronic stadium is similar to chronic ACD. Pruritus may be present, but the main 
symptoms may be burning and pain. It is usually sharply defined and does not disseminate [9]. 
 
Differential Diagnoses 
Numerous differentials must be considered, the primary being various types of dermatitis of different 
etiology including irritative-toxic dermatitis, atopic dermatitis, dyshidrotic dermatitis, nummular 
dermatitis, stasis dermatitis and lichen simplex chronicus [11]. Imitators of ACD that differ in 
pathophysiology and response to treatment include psoriasis, seborrheic dermatitis, pityriasis rosea, 
palmoplantar pustulosis, lichenoid dermatitis, lymphoma and tinea manuum [12]. Eczema can also 
occur as a secondary phenomenon such as in scabies where it occurs as a reaction to the mites’ 
feces, in phthiriasis, mycoses including candidiasis, and impetiginous infections. On the other hand, 
rarely ACD can also hide behind non-eczematous lesions such as erythema-multiform-like [13, 14], 
urticarial papular plaques, lichen-planus like and lichenoid eruptions [15], purpuric petechial reactions 
[16], dermal reactions [17], lymphomatoid contact dermatitis [18], granulomatous and pustular 
reactions [19] and finally pemphigoid-like lesions [20].  
 
Diagnosis 
Since it is very difficult to differentiate clinically between the various eczema entities, the collection of a 
precise medical history and a correct assignment of the morphologic patterns are the fundamental 
steps leading to find a proper diagnosis and guide subsequent patch tests.  
A useful history should include 
− Time of onset and possible contact with allergens or irritants (temporal relationship) 
− Contact area corresponding to reaction area 
− Initial clinical patterns and evolution of morphology 
− Working environment: exposure to potential allergens (even as unexpected as in phonecards 
[21]), dose, frequency, duration, protective measures such as gloves, masks and barrier creams 
and concomitant factors such as humidity, temperature, occlusion, friction 
− Similar situation in co-workers 
− Leisure activities 
− Domestic products, protective measures regarding cleaning works 
− Skin care products, fragrances, nail and hair products 
− Jewellery and clothing, communication devices 
− Suspicion regarding autotransfer, heterotransfer (e.g. connubial dermatitis), aerogen dermatitis, 
photo allergic dermatitis 
− History of previous dermatitis (past contact dermatitis, patch testing, atopic diathesis, family 
history) 
 
The clinical investigation should always register the body site and try to differentiate between probably 
primary site and spreading. It should be noted whether symmetry is present, erythema, fragile vesicles 
or dyshidrosiform sago-type vesicles, papules, scales, hyperkeratosis, lichenification, infiltration. 
Lesions compatible with a differential of ACD should be sought including for lichen planus and 
scabies. The nails must be examined for signs of dystrophy, onychomycosis or psoriasis (oil-spots).   
ACD and ICD are often co-existent. Also it is known that an allergic contact dermatitis often develops 
on the basis of an irritant CD. Constant irritation may lead to increased penetration of potential 
allergens. The detailed evaluation of a patient’s medical history and clinical features guides the 
selection of allergens for the patch test, which is the gold standard for diagnosis. Even though there 
rarely occur  type I hypersensitivity reactions such as the protein contact allergy [22], the 
overwhelming part of ACD is due to T-cell-mediated delayed type IV reactions.   
 
Patch Test 
Patch testing is by now the gold standard in diagnosing allergic contact eczema. It is the in vivo proof 
of the disease-causing effect of renewed contact with the allergen and evokes in small scale the 
elicitation phase of a delayed hypersensitivity (type IV) reaction. It involves the application of a series 
of allergens in specific chambers directly on the skin, mostly the upper back. 
Usually the specific allergens are carried on petrolatum-based vehicles in hypoallergenic chambers 
which are attached on the patient’s upper back. The standard series includes the most common 
allergens according to the German Contact Dermatitis Research Group (Table 1). A commercially 
available ready-made chamber system is called the T.R.U.E. Test which guarantees an exact 
standardized dosage and a high bioavailability for the allergens. Bioavailability depends on many 
factors such as intrinsic penetration capacity, concentration, vehicle, occlusivity of patch test system 
and tape and on the exposure time. The standardized T.R.U.E.-System therefore is a good option to 
avoid biased results [23, 24] – even though it is limited to a standard series of 35 common allergens 
that shows only partial overlap with the recommended standard series  [3]. 
In addition, the patients’ history and clinical features should prompt selection of additional panels for 
testing, as well as the patient’s own products in case of suspicion. Furthermore, an obligate irritant 
such as sodium lauryl sulphate 0,25 % or nonanionic acid, can be applied as a positive control to 
check the skin’s irritability at the time of exposure. A positive reaction of the sodium lauryl sulphate 
does not indicate an allergic reaction, it is purely irritant [25]. Patients under immunosuppression 
(including systemic steroids or active phototherapy at the side of testing) should not be tested because 
of false-negative results. This is even more important as the patch test does not include a positive 
control.  
The first reading of the test is performed at 48 hours, when the patches are removed again. In some 
clinics, patches are removed at 24 hours already. There is no strict agreement whether to keep it on 
for 24 hours or 48 hours. The reading should be done about half an hour after removing the test (after 
48 hours, see above), then after 72 hours and another time after 96 hours, especially if there are 
questionably positive results at 72 hours. A repeated reading after 1 week is highly suggested to not 
miss a delayed reaction (e.g. neomycin, corticosteroids) [9]. As for the analysis there are several 
scoring systems, a commonly used evaluation method is the system according to Wilkinson et al.  [26] 
(see Table 2). Reading and scoring have to be repeated at each individual visit to check the 
progression or regression of the reaction (day 2, day 3, day 4, or day 7). A modification has been 
proposed by Menné et al. (Table 3) [27], but to date, a world-wide consensus is lacking. Follicular 
reactions are not uncommon, i.e. to metals, and can be noted with an “f” beside the reaction intensity.  
An increasing reaction (crescendo) in patch testing is compatible with an allergic contact dermatitis, an 
initially positive and subsequently waning reaction (decrescendo) rather suggests an irritative cause. 
Positive reactions to chemically similar allergens may indicate cross reactions. Positive reactions to 
more than 5 non-related substances can on one hand indicate polysensibilisation [28], on the other 
hand an „angry back/excited skin syndrome“ must be considerered as well. [29, 30]. The latter can be 
ruled out by repeated testing of selected allergens about 2 months later.  
 
Limitations of Patch Testing 
Pooling of data and objective comparisons are limited by the current lack of standardization, which 
includes the source and amount of allergens, variation in materials (chambers, vehicles), variation in 
the type of occlusion, the duration of application, reading times and finally the score grading of patch 
test reactions. 
The amount of allergen is important, as the reactions can provoke either false-positive (e.g. by using 
an exaggerated quantity of the allergen, causing an irritation instead of an allergic reaction) or false-
negative reactions (e.g. by using too little amount of the allergen). Ready-made tests or testing 
preparations seek to overcome this problem. Petrolatum is the most commonly used carrier for 
allergens, with exception of the T.R.U.E. System which takes advantage of a dried-in-gel vehicle such 
as polyvidone or a cellulose derivate. Not all allergens are stable over time, several have a non-
satisfactory chemical stability caused by oxidation-progresses [9]. The highest objectivity in reading 
and scoring can be achieved by detailed description of the reaction seen, beside using a standardized 
score.   
Other disadvantages in patch testing are the possibilities to induce or reactivate hypersensitivity in 
sensibilized patients. Also, it can only be performed if there is no more active inflammation. The result 
could otherwise be false positive. No florid eczema or intense exposition to UV-light should precede 
the test. There is no data available regarding patch testing in pregnancy. For this reason the ICDRG 
advises against testing pregnant women [7]. Relating to medicaments and patch testing there is only 
unclear or controverse data available. As for corticosteroids there has not been found a consensus 
yet, but according to Lachapelle et al. patch testing in patients undergoing corticosteroid-therapy 
requires great caution in the evaluation phase [7] and we advise against it (see above). Likely, for 
antihistamines there is no general agreement, wherefore in most centers the treatment with 
antihistamines is paused while testing [31]. Finally, immunomodulators as a whole could alter the 
results [32] and whenever possible, they should be avoided during testing.  
 
Survey of Patch Test Reactions via Digital Imaging  
A recent pilot study, published by Boone et al. aims to distinguish doubtful (+?) allergic contact 
reactions from (IR) irritant reactions. As a High-Definition Optical Coherence Tomography (HD-OCT) it 
offers a non-invasive in vivo real-time three-dimensional measurement of the epidermal thickness. It 
showed that an increased thickness of the epidermis correlates with irritant reactions, which may be 
counter-inuitive for some experts. Furthermore, specific HD-OCT features corresponded with the 
severity of visual scoring. This peculiarity might lead to more objectivity in scoring of inflammatory 
reactions [33]. Standard three-dimensional photography may soon be available at sufficient resolution 
to reliably allow grading of reactions.   
 
Modifications of Patch Testing 
1. Strip Patch Test can increase sensitivity of patch testing by decreasing the thickness of the 
stratum corneum which results in a higher penetration of the allergens 
2. ROAT (= repeated open application test): repeated open application of an allergen over a few 
days, e.g. when patch testing in negative but ACD from a specific allergen is highly probable 
3. Atopy Patch Test: regarding diagnosis of areogenic or alimentary allergens in patients with 
atopic history, not yet sufficiently validated 
4. Scratch Testing 
5. Prick Testing in suspicion of type I allergy, such as protein contact allergy [3] 
 
In-vitro Tests 
In vitro lymphocyte stimulation tests expose blood-derived lymphocytes to controlled, purified amounts 
of allergens. A proliferation (traditionally measured with H3 Thymidine incorporation) correlating with 
increasing titers of allergen is interpreted as allergen-specific reaction. Especially for metal salts, these 
assays are validated very well. In vitro assays allow more control but have several disadvantages. For 
one, allergens must be free of non-specific stimulatory compounds such as lipopolysaccharide. 
Secondly, a proliferation to an allergen does not allow the conclusion that a manifest allergy is present. 
Thirdly, due to newer data [34] we are aware that the great majority of allergen-specific T cells are in 
the skin. Thus, the sensitivity of tests with peripheral blood mononuclear cells may not be very high. 
Fourth, the in vitro tests are very labour-intensive and have limited sensitivity and specificity. They are 
not standardized enough to be available as kits, instead, the tests must be performed by experienced, 
specialized laboratories and results must be carefully evaluated. Thus, they are not used for routine 
diagnostics for ACD [3, 35]. 
 
Treatment 
One of the most important measures in the prevention of ACD is avoidance of contact with the 
respective allergens. Often this is not feasible due to work or environmental circumstances. In these 
cases, patients need to be carefully instructed about protecting arrangements such as the wearing of 
appropriate clothes (e.g. gloves, masks) and barrier creams. 
Most frequently, acute and chronic ACD are treated with topical corticosteroids (Class II-III, most 
usually mometasone furoate or betamethasone). Even though palms and soles are not considered 
high risk regions of steroid-induced atrophy, quite often some atrophy is observed after long-term 
treatment and may contribute to the areas’ risk of being a minoris locus resistentiae to eczema. In 
these situations, and especially in areas with thinner epidermis such as the face of intertriginous 
areas, topical calcineurin-inhibitors (e.g. tacrolimus, pimecrolimus) are good choices for maintenance 
therapy after a short spell of steroids to reduce inflammation. They do not cause skin atrophy and 
have been shown to be useful to dampen chronic inflammation in atopic dermatitis [36]. In some 
cases, antihistamines can also reduce pruritus.  
Individuals with chronic allergic contact dermatitis may benefit from narrow-band UVB phototherapy or 
psoralen plus ultraviolet-A (PUVA) treatments. Systemic retinoids, foremost the new alitretinoin, but 
also acitretin, are very successful in treating eczema. Due to their teratogenicity, contraception is key. 
In special cases, a short systemic corticosteroid therapy can be useful, particularly in cases of 
systemic contact allergies as a result of hematogenic dissemination. Rarely also immunosuppressive 
agents such as cyclosporine,  azathioprine or mycophenolate are used in chronic ACD [3]. It remains 
unknown so far whether biologics such as the IL-4/-13 antagonist dupilumab or the IL-6 antagonist 
tocilizumab [37] are beneficial in ACD.  
 
Current controversies 
There may be few fields more controversial than ACD and its diagnostic techniques. Since the 
conception of the patch test by Josef Jadassohn (1863-1936) and further development by Bruno Bloch 
(1878-1933), every aspect of diagnosis and test has been challenged.  
Who should be patch tested – every eczematous dermatosis? A rule of thumb is that patch testing 
should produce positive test results between 30 and 65% of the time [38]. This may help clinicians to 
adjust their threshold of ordering patch tests accordingly, but helps little to decide whether a single 
patient should be patch tested or not. The most promising candidates for patch testing are 
eczematous disorders where ACD is suspected or failing to respond to treatment, chronic hand and 
foot dermatitis or stasis eczema, and also scattered generalized distribution of dermatitis.  
What standard series should be used, as it is different in every country? This is indeed controversial 
and not all selections seem to be strictly evidence-based and in accord with locally prevalent allergies. 
Also, minor factors such as the size of testing chambers can play a role on the outcome of patch 
testing.  
The interpretation of relevance of positive patch test reactions is a challenge for all dermatologists 
[39]. The circumstantial nature of the patch test does not allow a direct conclusion on the allergen 
causing the ACD, therefore each reaction must be considered in context with the patient’s history and 
clinical features.  
Our understanding of the pathophysiology of ACD may soon change somewhat. Traditionally, ACD is 
thought to be dependent on systemic presence of primed T cells that are expected to be everywhere 
in the skin. Therefore, a negative reaction in patch test is usually interpreted as an absence of 
sensitized T cells against the respective allergen in the tested patient. However, because newer data 
showed predominant numbers of T cells residing in the skin and staying locally for prolonged periods 
of time, it could well be that some contact allergies are local phenomena.  
The reasons for irritant and allergic reactions showing a remarkably similar histologic (including T cell 
infiltrates) and clinical patterns remain unclear. It could be that latent, perhaps non-specific T cells are 
expanded upon irritation of the skin, but this remains largely unproven.  
As to therapy of (atopic) eczema, some controversy was stirred by a recent paper showing application 
of topical steroids on presoaked skin (wet-wrap technique) not achieving improved outcome than 
application of topical steroids on dry skin [40].  
Taken together, the fascinating field of ACD continues to thrive and evolve. These conditions affect a 
high percentage of the population and are ideal targets for further investigation for prevention and 
treatment. In the future, we may see new forms of contact allergy diagnostics and hopefully 
standardized procedures for testing and interpretation of relevance of positive findings.  
  
Figure legend 
 
Figure 1 
A: Acute ACD to neomycin eye drops; B: Acute ACD to chromium; C: Chronic ACD 
 
Table legend 
 
Table 1:  
Standard patch test series recommended by the German Contact Dermatitis Research Group (DKG) 
[3].  
 
Table 2:  
Scoring of patch test reactions according to Wilkinson et al., on behalf of the ICDRG [26] 
 
Table 3:  
Scoring of patch test reactions, on behalf of ECDS and EECDRG [27] 
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Table 1:  
Name of substance  Vehicle Concentration 
Potassium dichromate PET 0.5 % 
Thiuram mix PET 1 % 
Cobalt (II) chloride, 6*H2O PET 1 % 
Balsam of Peru PET 25 % 
Colophony PET 20 % 
N-isopropyl-N’-phenyl paraphenylenediamine PET 0.1 % 
Wool alcohols PET 30 % 
Mercapto mix without MBT (only CBS, MBTS, MOR) PET 1 % 
Epoxy resin PET 1 % 
Nickel (II) sulphate, 6*H2O PET 5 % 
Paratertiarybutyl phenol formaldehyde resin PET 1 % 
Formaldehyde AQU 1 % 
Fragrance mix PET 8 % 
Turpentine PET 10 % 
(Chloro)-methylisothiazolinone (MCI/MI) AQU 100 ppm 
Paraben mix PET 16 % 
Cetyl stearyl alcohol   PET 20 % 
Zinc bis(diethyldithiocarbamate)    PET 1 % 
Dibromodicyanobutane (methyldibromo glutaronitrile) PET 0.2 % 
Propolis PET 10 % 
Bufexamac PET 5 % 
Compositae mix II PET 5 % 
Mercaptobenzothiazole PET 2 % 
Hydroxymethylpentylcyclohexenecarboxaldehyde (Lyral) PET 5 % 
Bronopol (2-bromo-2-nitropropane-1,3-diol) PET 0.5 % 
Fragrance mix II PET 14 % 
Sodium lauryl sulphate AQU 0.25 % 
Ylang-ylang (I + II) oil PET 10 % 
Sandlewood oil PET 10 % 
Jasmine absolute PET 5 % 
 
  
Table 2: 
 
 
 
 
  
Score Interpretation 
- Negative reaction 
?+ Doubtful reaction; faint erythema only, not considered proven allergic reaction 
+ Weak (nonvesicular) reaction; erythema, slight infiltration 
++ Strong (edematous or vesicular) reaction; erythema, infiltration, vesicles 
+++ Extreme (bullous or ulcerative) 
IR Irritant reactions of different types 
NT Not tested 
  
Table 3: 
 
 
 
 
 
 
 
 
 
 
Score Interpretation 
+ Homogeneous redness in the test area with scattered papules 
++ Homogeneous redness and homogeneous infiltration in the test area 
+++ Homogeneous redness and infiltration with vesicles 
++++ Homogeneous redness and infiltration with coalescing vesicles 
